Massive RSV vaccine trial aims to keep adults out of the hospital

NCT ID NCT06684743

First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 14 times

Summary

This large study is testing whether the Abrysvo RSV vaccine can prevent adults from being hospitalized due to RSV. About 690,000 adults aged 18 and older will be randomly assigned to receive either the vaccine or no vaccine. The main goal is to see if the vaccine reduces RSV-related hospital stays.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte

    NOT_YET_RECRUITING

    Copenhagen, 2900, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Danske Lægers Vaccinations Service

    RECRUITING

    Søborg, 2860, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • General Public Health Directorate of Galician Health Service

    RECRUITING

    Santiago de Compostela, A Coruña, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.